Thermo Fisher Scientific Inc
I · Analyse IA
En bref
Thermo Fisher supplies the tools, chemicals, and services that pharmaceutical companies and research labs need to discover drugs, manufacture medicines, and run diagnostic tests. They operate across four segments: Life Sciences Solutions (research reagents and instruments), Analytical Instruments (lab equipment), Specialty Diagnostics (clinical testing products), and Laboratory Products and Biopharma Services (contract manufacturing and research services for drug companies).
Thermo Fisher Scientific is a $166.4 billion life sciences and laboratory equipment company that provides instruments, reagents, diagnostics, and contract manufacturing services to pharmaceutical, biotech, and research customers worldwide [Yahoo Finance]. The company serves as a critical infrastructure provider for drug development, with recent growth driven by expanding bioprocess services, new laboratory facilities in Sweden, and partnerships to manufacture oncology drugs [Yahoo Finance]. Despite solid fundamentals, the stock has significantly underperformed the market over the past year, rising only 8.3% compared to the S&P 500's 25.2% gain [Yahoo Finance].
Thermo Fisher shows solid profitability with moderate leverage, though return on capital and stock performance lag expectations.
Score Sentinellis
6.8/10
Moderate concerns
Capitalisation boursière
$166.4B
Chiffre d'affaires (12 mois)
$44.6B
II · Actualités récentes
Ce qui a fait bouger le cours
6 stories · ranked by relevance
- macro2026-05-20
Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation at 2026 Investor Day
Yahoo Finance
- macro2026-05-19
Global Cell Culture Media Market Outlook 2026-2036: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG
Yahoo Finance
- macro2026-05-18
Life Science Instrumentation Market Forecast Report 2025-2031: Expanding Activities in Genomics, Proteomics, and Drug Discovery with Thermo Fisher Scientific, Danaher, Agilent, and Shimadzu Leading
Yahoo Finance
- macro2026-05-18
Nuvation Bio Sharpens IBTROZI Focus With Thermo Fisher And FDA Steps
Simply Wall St
- macro2026-05-18
Thermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden
Yahoo Finance
- macro2026-05-18
Thermo Fisher Deepens Oncology Role With Ibtrozi Manufacturing Milestone
Simply Wall St
Premium · gratuit avec tout compte
The stock has badly underperformed the market, gaining only 8.3% over the past year while the S&P 500 rose 25.2%, and is down 24.4% year-to-date versus an 8.1% market gain [Yahoo Finance]. This persistent weakness suggests investor concerns about growth trajectory or valuation.
Risques
4
Opportunités
5
Signaux d'alerte
1
Direction
10
19 autres constats dans le rapport complet — gratuit avec tout compte.
Débloquer l'analyse complète de Thermo Fisher Scientific Inc
Créez un compte gratuit pour accéder au rapport complet généré par IA, avec les sources citées dans le texte.
- 4 risques, 5 opportunités et 1 signal d'alerte — chacun avec sa source
- Plus de 100 indicateurs financiers avec graphiques et comparaisons
- Résumés d'actualités complets avec liens vers les sources
- Équipe dirigeante et rémunération
- Export PDF pour la lecture hors ligne
III · Entreprises similaires
À lire également
Same sector · Healthcare or comparable health
L'ajouter à votre liste ?